Investor Presentation Full Year 2021
92
Investor presentation Full year 2021
International Operations at a glance.
Novo NordiskⓇ
Million
Diabetes trend
DKK
billion
22%
200
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
Full year 2021
Sales
(mDKK)
Growth²
80%
Total GLP-13
16,106
52%
600
I
26%
Long-acting insulin4
11,074
13%
GLP-1
150
60%
Premix insulin5
10,512
4%
31%1
400
I
Fast-acting insulin
10,903
3%
Insulin
Human insulin
7,453
3%
100
5%1
40%
637
Total insulin
39,942
6%
522
Other Diabetes care?
2,644
(10%)
200
415
50
20%
Diabetes care
58,692
14%
7%1
OAD
Obesity care
3,117
52%
(SaxendaⓇ)
0
2019
2030
0
Nov
2045
2016
0%
Diabetes & Obesity
61,809
16%
Nov
2021
care
Population with diabetes
Diabetes growth rate
Biopharm³
11,728
3%
GLP-1 MS -Insulin MS
-OAD MS
Total
73,537
14%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 1th Edition 2000 and Diabetes Atlas 9th Edition 2019
1 CAGR calculated for 5-year period; Competitor insulin value market
shares, as of Nov 2021: Novo Nordisk 50%, Sanofi 27% and Eli Lilly 14%;
Competitor GLP-1 value market shares, as of Nov 2021: Novo Nordisk
59%, Eli Lilly 38% and AstraZeneca 3%; OAD: Oral anti-diabetic; MS:
Market share; Source: IQVIA MAT, Nov 2021 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ; 5 Comprises RyzodegⓇ and
NovoMix: 6 Comprises Fiasp® and NovoRapid®; 7 Comprises Novo NormⓇ and
needles; 8 Comprises primarily Novo Seven®, Novo Eight® NovoThirteenⓇ,
Refixia®, Esperoct®, Norditropin®, Vagifem® and ActivelleⓇView entire presentation